ReviewClinical journal of the American Society of Nephrology : CJASN2013
Cardiorenal syndrome: ultrafiltration therapy for heart failure--trials and tribulations.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Defining the role of ultrafiltration therapy in acute heart failure: a systematic review and meta-analysis.Heart failure reviews · 2016Pooled it
- Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open-label, controlled phase II clinical trial.Stem cells translational medicine · 2020Trial
- The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation.Kidney international reports · 2026Review
- Empagliflozin protected kidney function in CKD rat through suppressing hypoxic and fibrotic signalings mediated inflammation and EMT.Histology and histopathology · 2026Article
- Device-based therapies in cardio-renal syndrome: a pathophysiology-driven approach to a complex bidirectional disease.Frontiers in cardiovascular medicine · 2026Review
- Heart Failure-Focus on Kidney Replacement Therapy: Why, When, and How?International journal of molecular sciences · 2025Review
- Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction.Journal of cardiovascular development and disease · 2024Review
- Article
- Intrarenal arterial administration of human umbilical cord-derived mesenchymal stem cells effectively preserved the residual renal function of diabetic kidney disease in rat.Stem cell research & therapy · 2022Article
- Overexpression of miR-19a and miR-20a in iPS-MSCs preserves renal function of chronic kidney disease with acute ischaemia-reperfusion injury in rat.Journal of cellular and molecular medicine · 2021Article
- Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management.Cureus · 2021Review
- Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature.British journal of pharmacology · 2020Review
- Intravenous administration of iPS-MSCJournal of cellular and molecular medicine · 2020Article
- SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill.Proceedings (Baylor University. Medical Center) · 2020Review
- Extracorporeal shock wave treatment attenuated left ventricular dysfunction and remodeling in mini-pig with cardiorenal syndrome.Oncotarget · 2017Article
- Fluid overload as a major target in management of cardiorenal syndrome: Implications for the practice of peritoneal dialysis.World journal of nephrology · 2017Review
- Article
- Current Approach to Decongestive Therapy in Acute Heart Failure.Current heart failure reports · 2015Review
- [Renal dysfunction in heart failure and hypervolumenia : Importance of congestion and backward failure].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- Cardiorenal syndrome: introduction.Clinical journal of the American Society of Nephrology : CJASN · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure remains the leading cause of hospitalization in older patients and is considered a growing public health problem with a significant financial burden on the health care system. The suboptimal efficacy and safety profile of diuretic-based therapeutic regimens coupled with unsatisfactory results of the studies on novel pharmacologic agents have positioned ultrafiltration on the forefront as an appealing therapeutic option for patients with acute decompensated heart failure (ADHF). In recent years, substantial interest in the use of ultrafiltration has been generated due to the advent of dedicated portable devices and promising results of trials focusing both on mechanistic and clinical aspects of this therapeutic modality. This article briefly reviews the proposed benefits of ultrafiltration therapy in the setting of ADHF and summarizes the major findings of the currently available studies in this field. The results of more recent trials on cardiorenal syndrome that present a counterpoint to previous observations and highlight certain limitations of ultrafiltration therapy are then discussed, followed by identification of major challenges and unanswered questions that could potentially hinder its more widespread use. Future studies are warranted to shed light on less well characterized aspects of ultrafiltration therapy and to further define its role in ADHF and cardiorenal syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.